If you have spent the last week in a haze of carpeted convention centers, lukewarm coffee, and thousands of brief, high-intensity meetings, you aren’t alone. BIO is the "Super Bowl" of biotech partnering, and for many, it is the single most exhausting week on the annual calendar. But here is the cold, hard reality: If your BIO follow-up plan consists of an inbox blast saying “great to meet you,” you have effectively wasted your company’s capital.
In my eleven years of building conference portfolios for mid-size biotech and top-15 pharma, I’ve seen teams return from these events with pockets full of business cards and CRMs full of empty promises. They treat the event as a destination. It’s not. It’s a starting gun. If you didn’t define what "success" looked like before you stepped on the floor, you weren’t executing a strategy; you were on an expensive field trip.
In this post, we’re going to kill the hype. Here's a story that illustrates this perfectly: thought they could save money but ended up paying more.. We’re going to build a rigorous, follow-up-focused engine for your partnering pipeline, ensuring that your time at BIO actually moves the needle on your licensing next steps.
The "Big but Useless" List: Why You Are Wasting Your Time
Before we talk about follow-ups, we need to address the "Conference Ego." We love to attend meetings that "look big." If you are attending events simply because everyone else is there, or because your leadership team wants to feel like they are "in the mix," you are falling for the biggest trap in the industry. Here are a few meetings that often look big but deliver near-zero tangible outcomes for commercial adoption or licensing:
- "Industry Mixer" Panels: Where the networking is just people handing out cards they will lose by the hotel bar. Broad-Scope General Assemblies: If you aren't there for a specific deal or a specific stakeholder, you’re just a spectator. "Thought Leadership" Dinners: Unless you are there to close a specific gap in your commercial intelligence or secure a meeting with a high-value stakeholder, these are just expensive social events.
Stop calling these "must-attend" FDA EMA MHRA town hall events. If it doesn't feed your CRM with qualified leads or advance an active deal, it’s a vanity metric.
Building Your Post-BIO Follow-Up Architecture
The BIO Partnering platform is a treasure trove of data, but most teams treat it like a digital directory. Instead, you need to treat it like a CRM integration project. Here is how to actually move the needle after the event.
1. Data Normalization (Immediately)
Within 48 hours of returning, every interaction must be logged into your central CRM—not a shared spreadsheet, not your inbox. Use the tagging system in the BIO Partnering platform to identify "Hot," "Warm," and "Long-term" leads.
2. The Three-Tiered Follow-Up Strategy
Not every partner is equal. Your follow-up must be tiered based on the specific asset or licensing goal. Stop sending mass mailers.
https://highstylife.com/stop-chasing-hype-how-biotech-startups-should-actually-select-q1-conferences/ Tier Goal Action Required Tier 1 (Hot) Immediate Term Sheet/Due Diligence Direct call from a lead BD or Medical Affairs head within 72 hours. Tier 2 (Warm) Follow-up data request/Capability match Personalized email with requested data packets; schedule a follow-up video call. Tier 3 (Cold/Future) Long-term relationship nurturing Add to a specific newsletter/content track; quarterly check-in cadence.The Annual Anchor Strategy: Connecting BIO, Fierce Pharma, and THMA
One of the reasons many teams fail is that they treat conferences as isolated events. I structure a year-long program by ensuring one event informs the next. You need to map your commercial execution across three distinct phases of your pipeline:
The Summer Anchor: BIO (Partnering & Licensing)
BIO is your anchor for high-level asset movement. This is where you identify the "Who" and the "How much." The follow-up here isn't about marketing—it's about technical validation. Your next steps should be: "Have we scheduled the initial data-room review for this asset?" If that question isn't answered by July 1st, your BIO follow-up has stalled.
The Execution Phase: Fierce Pharma Week (Commercial & CI)
Once you’ve identified your partners at BIO, move toward commercial execution. Fierce Pharma Week is where you sharpen the blade. You go here not to "partner," but to gather competitive intelligence on how your commercial launch plan stacks up against the broader market. You are checking your assumptions: Is our messaging actually resonating with the broader commercial ecosystem, or are we just echoing our own hype?
The Reality Check: The Health Management Academy (THMA)
This is where the rubber meets the road. If you are developing a drug or a therapy, you eventually have to get it on a formulary. THMA forums are essential for understanding health system adoption. The disconnect between a "great licensing deal" and "actual patient access" is massive. By the time you reach the THMA forums, you should be asking, "Does our licensing structure allow for the flexibility required by these specific health systems?"
A Simple Checklist for Your BIO Follow-Up
Forget the vague "Let's connect next week" email. Use this checklist to ensure you’re moving your partnering pipeline forward:
Conclusion: Stop Tracking "Activity" and Start Tracking "Outcomes"
When I lead programming for pharma teams, I tell them: ROI isn't about how many people you met; it's about how many roadblocks you removed.
If you walk away from BIO with a full card stack but no new insight into why a deal *won't* work, you have failed. The goal of the post-conference follow-up is not to keep the conversation "alive." The goal is to reach a definitive "yes" or "no" as efficiently as possible. Whether you are dealing with a potential licensee or exploring a path to a major health system through THMA, the process remains the same: define the objective, track the conversion, and kill the distractions.
You have the data from the BIO platform. You have the strategic context from the rest of your annual portfolio. Now, stop the "hand-wavy" follow-ups and start driving the deal. The industry doesn't reward the team that attended the most parties; it rewards the team that turned a 20-minute meeting into a transformative license.. Pretty simple.
Quick Tips for Implementation:
- Automate the CRM, not the Relationship: Use automation to update the database, but keep the email correspondence strictly 1:1. Avoid "Marketing Speak": When following up, focus on the technical or commercial value-add. Avoid vendor-deck language that hides the real status of the partnership. Prioritize the "Hard" Questions: If you had a great meeting, the follow-up should be the time to bring up the hardest question regarding the deal. Don't wait three months to find out it won't work.
If you follow this framework, you’ll find that by the time next year’s conference season rolls around, you aren't just "attending"—you’re closing.